Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Finalizes Split with Acacia Research, Begins Trading on Nasdaq

NEW YORK (GenomeWeb News) - CombiMatrix has completed its split from former parent company Acacia Research through a share swap and this morning began trading on the Nasdaq Capital Market, the companies said today in separate statements.
The US Securities and Exchange Commission approved the break-up plan in June.
CombiMatrix initially filed its plan to split from Acacia in December 2006. CEO Amit Kumar said at the time that the split would enable each company to forge independent business plans, and would afford CombiMatrix the freedom to “invent ourselves with a focus on molecular diagnostics and personalized medicine.”
The split took place through a share trade, under which every 10 shares of Acacia Research-CombiMatrix common stock was traded for one share of CombiMatrix common stock.
CombiMatrix began trading today under the symbol “CBMXD,” but will shift to “CBMX” after 20 days, at which time Acacia will begin trading under the symbol “ACTG.”
Shares opened today at $5.96 a share, and were down more than 7 percent, to $5.55 a share, in mid-afternoon trading.
The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.